Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

Cabibbo, Giuseppe; Petta, Salvatore; Barbàra, Marco; Attardo, S.; Bucci, Laura; Farinati, Fabio; Giannini, Edoardo G.; Negrini, Giulia; Ciccarese, Francesca; Rapaccini, Gian Lodovico; Marco, Maria Di; Caturelli, Eugenio; Zoli, Marco; Borzio, Franco; Sacco, Rodolfo; Virdone, Roberto; Marra, Fabio; Mega, Andrea; Morisco, Filomena; Benvegnù, Luisa; Gasbarrini, Antonio; Svegliati‐Baroni, Gianluca; Foschi, Francesco Giuseppe; Olivani, Andrea; Masotto, Alberto; Nardone, Gerardo; Colecchia, Antonio; Persico, Marcello; Craxı̀, Antonio; Trevisani, Franco; Cammà, Calogero

doi:10.1016/j.jhep.2017.01.033

Cited by 85 publications

(81 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also showed that 17% of the HCC recurrences had an infiltrative pattern, like data by Reig et al Furthermore, long‐term prospective studies are necessary to better substantiate the benefit of SVR on liver decompensation and death. Consistently, we recently demonstrated that hepatic decompensation, not HCC early recurrence, is the major driver of death in patients untreated for HCV with successfully treated HCC …”

Section: Discussionsupporting

confidence: 66%

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Cabibbo¹,

Petta²,

Calvaruso³

et al. 2017

Aliment Pharmacol Ther

140

125

View full text Add to dashboard Cite

Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.

show abstract

Section: Discussionsupporting

confidence: 66%

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Cabibbo¹,

Petta²,

Calvaruso³

et al. 2017

Aliment Pharmacol Ther

140

125

View full text Add to dashboard Cite

show abstract

“…Also this study confirms the absence of alarms and strengthens that the proven benefit on hepatic decompensation overcomes the unlikely effect of DAAs on the risk of HCC [14].…”

Section: Manuscriptsupporting

confidence: 83%

Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?

Maida¹,

Cabibbo

Cammà

2018

Expert Review of Anticancer Therapy

Self Cite

View full text Add to dashboard Cite

“…The survival of patients with HCC is strongly influenced by factors related to the residual liver function and to decompensation of the underlying liver cirrhosis [53]. In addition, the development of new HCC foci with a dissemination potential and immunogenicity different from that of the primary tumor cannot be excluded and may play a role in the subsequent evolution of the disease.…”

Section: Discussionmentioning

confidence: 99%

Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: The antitumor immune response may play a major role in the clinical outcome of hepatocellular carcinoma (HCC). We characterized the liver immune microenvironment by direct hybridization of RNA extracted from HCC and nontumorous tissues. Methods: RNA was extracted from frozen liver tissue samples of HCC (T; n = 30) and nontumorous tissues (NT; n = 33) obtained from 38 patients. Matched samples were available for 25 patients. The immune gene expression profile was analyzed with the nCounter GX Human Immunology v2 system (NanoString Technologies), which detects the expression levels of 579 immune response-related genes simultaneously. Results: Since the immune gene expression profile of T and NT tissues was significantly different, the prognostic relevance of the liver immune microenvironment was evaluated in the T and NT samples separately. Unsupervised clustering detected two main clusters of immune gene expression both in T and in NT liver samples. In both cases, the expression clusters identified groups of patients with a significantly different median time to HCC recurrence (TTR) but similar overall survival. Based on T tissue, two groups with median TTR of 19 and 127 months, respectively, were detected (p < 0.005). Expression of genes related to T-cell activation was associated with longer TTR. The analysis of NT tissue discriminated subsets of patients with median TTR of 22 and 68 months (p < 0.05). In contrast to T tissue, a predominant inflammatory immune environment was associated with shorter TTR. Conclusions: Immune gene expression profiles predictive of TTR could be identified both in HCC and in adjacent cirrhotic tissues. Longer TTR was associated with overexpression in T tissue and downregulation in NT tissue of the immune response and of inflammation-related genes.

show abstract

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

Cited by 85 publications

References 33 publications

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?

Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence

Contact Info

Product

Resources

About